Teva Pharmaceutical Industries, founded in 1901 in Jerusalem, evolved from a small wholesale drug business into the world's largest generic drug manufacturer, navigating mergers, acquisitions, and regulatory challenges while maintaining a strong presence on the Tel Aviv Stock Exchange.
Teva is founded in Jerusalem as a small wholesale drug business by Chaim Botzer and Moshe Levin. The company initially imports and distributes pharmaceuticals. #pharma #israel
Teva transitions from distribution to manufacturing, producing its own pharmaceutical products in a small facility. This marks the start of its industrial operations. #pharma #manufacturing
Following the establishment of the State of Israel, Teva expands its production capacity to meet growing domestic demand for medicines. #israel #pharma
Teva goes public on the Tel Aviv Stock Exchange (TASE), providing capital for expansion and increasing its corporate profile. #ipo #tase
Teva acquires Assia Chemical Laboratories, a major Israeli drug manufacturer, significantly increasing its product portfolio and market share. #acquisition #pharma
Teva merges with Zori and Ikapharm to form Teva Pharmaceutical Industries Ltd., creating a stronger domestic entity. #merger #pharma
Teva begins development of Copaxone (glatiramer acetate), a groundbreaking multiple sclerosis drug that later becomes a blockbuster. #pharma #ms
Teva establishes its first U.S. subsidiary, Teva Pharmaceuticals USA, marking its entry into the American generics market. #expansion #usa
Teva lists on NASDAQ under the ticker TEVA, raising capital for international growth. #ipo #nasdaq
Teva acquires Lemmon Company, a U.S. generic drug manufacturer, significantly expanding its American operations. #acquisition #generics
Copaxone receives FDA approval for relapsing-remitting multiple sclerosis, becoming Teva's first proprietary blockbuster drug. #fda #ms
Teva acquires Novopharm, a Canadian generic company, strengthening its North American presence. #acquisition #canada
Teva acquires IVAX Corporation for $7.6 billion, becoming the world's largest generic drug manufacturer. #acquisition #generics
Teva launches the first generic version of the blockbuster drug Protonix (pantoprazole), cementing its leadership in generics. #generics #launch
Teva acquires Barr Pharmaceuticals for $7.46 billion, expanding its women's health and specialty products. #acquisition #pharma
Teva acquires Ratiopharm, a German generic drug maker, for €3.6 billion, strengthening European operations. #acquisition #europe
Teva launches the first generic version of Lipitor (atorvastatin), the world's best-selling drug, under a settlement with Pfizer. #generics #lipitor
Teva settles patent litigation with Mylan over Copaxone, extending market exclusivity and avoiding immediate generic competition. #patent #litigation
Teva acquires Auspex Pharmaceuticals for $3.5 billion, gaining potential treatments for Huntington's disease and Tourette syndrome. #acquisition #biotech
Teva acquires Allergan's generics business for $40.5 billion, becoming a dominant player in the global generics market. #acquisition #generics
Erez Vigodman steps down following declining profits and debt concerns from the Allergan acquisition. #ceo #resignation
Kåre Schultz becomes CEO, tasked with restructuring Teva's debt and operations. #ceo #restructuring
Teva's debt surpasses $30 billion, and its stock price plummets, leading to restructuring and layoffs. #debt #restructuring
Teva announces a global restructuring plan, including plant closures, R&D cuts, and workforce reductions to save $3 billion annually. #restructuring #layoffs
Teva reaches a $85 million settlement with two Ohio counties over its role in the opioid crisis, part of broader litigation. #opioid #litigation
Teva receives FDA approval for a biosimilar of adalimumab (Humira) in partnership with Celltrion, entering the biosimilars market. #biosimilar #fda
Teva reduces its net debt to around $20 billion, showing progress under Schultz's turnaround plan. #debt #turnaround
Teva launches the first generic version of Restasis (cyclosporine), a dry eye treatment, boosting its generics pipeline. #generics #launch
After six years, Kåre Schultz retires as CEO, succeeded by Richard Francis. #ceo #transition
Teva agrees to a $3.8 billion settlement with states and counties over opioid claims, resolving major litigation. #opioid #settlement
Teva advances several biosimilars in late-stage development, including candidates for cancer and autoimmune diseases. #biosimilar #pipeline
New CEO Richard Francis announces a 'Pivot to Growth' strategy, focusing on innovative medicines and biosimilars. #ceo #strategy
Teva enters a $3 billion partnership with Sanofi to develop and commercialize an anti-TL1A antibody for inflammatory bowel disease. #partnership #biotech
Richard Francis presents a 5-year plan targeting $5 billion in revenue from new products by 2030. #growth #strategy
Teva reports its first annual profit since 2017, driven by cost cuts and new product launches. #profit #earnings